Terug
70
Dagbereik
€ 62,80
€ 64,87
52-Weeksbereik
€ 60,70
€ 88,20
Volume
1.344.547
50D / 200D Gem.
€ 75,06
/
€ 75,07
Vorige Slotkoers
€ 65,69
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 7,1 | 0,3 |
| P/B | 2,2 | 2,9 |
| ROE % | 38,9 | 3,7 |
| Net Margin % | 18,7 | 3,8 |
| Rev Growth 5Y % | 0,5 | 10,0 |
| D/E | 1,0 | 0,2 |
Koersdoel Analisten
Hold
€ 95,80
+49.6%
Low: € 77,00
High: € 105,00
Forward K/W
10,2
Forward WPA
€ 6,48
WPA Groei (sch.)
+0,0%
Omzet Sch.
8,2 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 0,00
€ 0,00 – € 0,00
|
9 B | 0 |
| FY2028 |
€ 7,83
€ 3,96 – € 11,70
|
8,8 B | 2 |
| FY2027 |
€ 7,07
€ 6,92 – € 7,24
|
8,5 B | 7 |
Belangrijkste Punten
Revenue grew 0,47% annually over 5 years — modest growth
Earnings grew 224,84% over the past year
ROE of 38,86% indicates high profitability
Net margin of 18,69% shows strong profitability
Negative free cash flow of -10,00M
P/E of 7,14 — trading at a low valuation
Groei
Revenue Growth (5Y)
0,47%
Revenue (1Y)0,86%
Earnings (1Y)224,84%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
38,86%
ROIC16,22%
Net Margin18,69%
Op. Margin26,20%
Veiligheid
Debt / Equity
1,00
Current Ratio1,23
Interest Coverage6,29
Waardering
P/E Ratio
7,14
P/B Ratio2,20
EV/EBITDA7,00
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0,86% | Revenue Growth (3Y) | 0,78% |
| Earnings Growth (1Y) | 224,84% | Earnings Growth (3Y) | 7,52% |
| Revenue Growth (5Y) | 0,47% | Earnings Growth (5Y) | 1,60% |
| Profitability | |||
| Revenue (TTM) | 8,33B | Net Income (TTM) | 1,56B |
| ROE | 38,86% | ROA | 10,89% |
| Gross Margin | 53,47% | Operating Margin | 26,20% |
| Net Margin | 18,69% | Free Cash Flow (TTM) | -10,00M |
| ROIC | 16,22% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,00 | Current Ratio | 1,23 |
| Interest Coverage | 6,29 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 7,14 | P/B Ratio | 2,20 |
| P/S Ratio | 1,33 | PEG Ratio | 0,04 |
| EV/EBITDA | 7,00 | Dividend Yield | 0,00% |
| Market Cap | 11,11B | Enterprise Value | 15,27B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8,33B | 8,25B | 8,20B | 8,13B | 8,17B |
| Net Income | 1,56B | 479,00M | 1,35B | 1,34B | 1,46B |
| EPS (Diluted) | 8,88 | 2,76 | 7,79 | 7,79 | 8,47 |
| Gross Profit | 4,45B | 4,59B | 4,69B | 4,70B | 4,92B |
| Operating Income | 2,18B | 1,04B | 1,69B | 1,69B | 1,88B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 14,29B | 14,46B | 13,94B | 13,59B | 14,08B |
| Total Liabilities | 9,25B | 11,50B | 2,28B | 1,85B | 2,02B |
| Shareholders' Equity | 5,05B | 2,96B | 11,67B | 11,74B | 12,06B |
| Total Debt | 5,04B | 8,01B | 8,30B | 0,0 | 0,0 |
| Cash & Equivalents | 878,00M | 762,00M | 194,00M | 61,00M | 91,00M |
| Current Assets | 3,86B | 3,25B | 2,52B | 2,23B | 2,19B |
| Current Liabilities | 3,14B | 2,70B | 1,73B | 1,31B | 1,41B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#50 of 670
Recente Activiteit
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026